CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
CytoDyn has completed enrollment in its Phase 2 CLOVER study, randomizing approximately 60 patients to evaluate leronlimab in combination with TAS-102 and bevacizumab for metastatic colorectal cancer. The trial targets CCR5-positive, microsatellite stable patients who have relapsed or are refractory to prior standard therapies across seven U.S. clinical sites.
Key figures
- Drug Name
- leronlimab
- Phase Of Trial
- Phase 2
- Enrolled patients
- Approximately 60
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.